US2023265526A1PendingUtilityA1
Cd133 related to anticancer agent resistance in colon cancer and use thereof
Assignee: UNIV KOREA RES & BUS FOUNDPriority: Apr 15, 2019Filed: Mar 17, 2023Published: Aug 24, 2023
Est. expiryApr 15, 2039(~12.7 yrs left)· nominal 20-yr term from priority
G01N 33/57535G01N 33/5758C12Q 1/6886A61K 48/00C12N 15/113A61K 45/06C12Q 2600/106C12Q 2600/158C12N 15/1138C12N 2310/14A61K 38/00A61K 31/7105A61K 31/713G01N 2333/70596G01N 2800/52C12N 5/0006
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.
Claims
exact text as granted — not AI-modified1 . A method of treating resistance to Gefitinib in colon cancer, the method comprising administering an inhibitor against a CD133 gene to a subject resistant to Gefitinib, wherein the inhibitor is a peptide, a compound, or an antibody against the CD133 protein.
Join the waitlist — get patent alerts
Track US2023265526A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.